Levamisole in Crohn's disease--a double-blind controlled trial.
The efficacy of levamisole in patients with mildly active Crohn's disease was evaluated in a double-blind, placebo-controlled trial by means of clinical, biochemical, and immunological parameters. No immunosuppressive drugs were prescribed during the study. 11 patients received levamisole for 3 months (2.5 mg/kg body weight on 2 consecutive days/week) and 10 patients received placebo. Although the 2 patients groups were not very well comparable, the overall results of this study did not show obvious changes in clinical, biochemical, or immunological parameters in either group. No side effects of levamisole were observed during the study.
D000328:Adult; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007978:Levamisole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010587:Phagocytosis / Q000187:drug effects; D010919:Placebos
D007136:Immunoglobulins; D010919:Placebos; D007978:Levamisole